Phaseline

Targets › HMPV

HMPV: drug programs, companies and trials

4 programs from 2 companies in 8 trials: 7 Phase 1, 1 Phase 2; Infectious disease, Vaccines; next expected readout Jan 2027.

Open in Phaseline: the race on HMPV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SanofiBivalent RSV+HMPV protein vaccine (RPF08203)
Respiratory syncytial virus and human metapneumovirus protein vaccine
RSVA, RSVB, HMPVPhase 2Respiratory Syncytial VirusJul 2028
SanofiInvestigational hMPV/RSV vaccine
mRNA vaccine encapsulated in lipid nanoparticle targeting hMPV and RSV
HMPV, RSVPhase 1Human Metapneumovirus ImmunizationJan 2027
ModernaTXmRNA-1365 (Profile 2)
mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV)
RSV, HMPVPhase 1Respiratory Syncytial Virus (RSV); Respiratory Syncytial VirusJul 2027
SanofiRSV + HMPV Candidate Vaccine
Live attenuated or recombinant viral vaccine against respiratory syncytial virus and human
RSV, HMPVPhase 1Respiratory Syncytial Virus ImmunizationMay 2028

Conditions

Human Metapneumovirus Immunization (4) Respiratory Syncytial Virus (2) Respiratory Syncytial Virus Immunization (1) Respiratory Syncytial Virus (RSV) (1)

Modalities

other (4)

Companies

Sanofi (3) ModernaTX (1)

Related targets

RSV (3) RSVA (1) RSVB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.